Tempero Bio

Tempero Bio is a clinical-stage biopharmaceutical company developing treatments for Substance Use Disorders and related disorders. Tempero Bio is a portfolio company of Aditum Bio, the biotech investment firm co-founded in 2019 by former Novartis CEO Joe Jimenez and former President of the Novartis Institutes for BioMedical Research (NIBR) Dr. Mark Fishman. Our lead therapeutic drug candidate, TMP-301, is a potent, orally available, metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM) that is being investigated for the treatment of Substance Use Disorders, including Cocaine Use Disorder (CUD) and Alcohol Use Disorder (AUD). Additional discovery is also underway on the potential of TMP-301 to treat other addictive disorders, such as Methamphetamine Use Disorder (MUD) and Polysubstance Use Disorder (PUD).